Emerging CELMoDs in Multiple Myeloma

The discussion expands to investigational CELMoDs in multiple myeloma, focusing on cemsidomide and the ongoing MOMENTUM trial. Dr. Goldsmith and Dr. Richardson discuss early clinical experience with cemsidomide and how its molecular structure and protein-degradation properties may differ from those of iberdomide and mezigdomide. The panel notes that neutropenia remains an important adverse effect and emphasizes that additional clinical data are needed to understand how cemsidomide may compare with other CELMoDs. Dr. Richardson also discusses the possibility of sequential treatment with different CELMoDs, while emphasizing that comparative evidence is not yet sufficient to establish one agent as superior to another. The conversation highlights the potential value of having multiple oral protein degraders available as the multiple myeloma treatment landscape evolves. Dr. Mikhael closes the section by summarizing the emerging clinical role of CELMoDs and transitions to the second module, which will explore their application in clinical scenarios.